Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of prexasertib in treating
pediatric patients with solid tumors that have come back after a period of time during which
the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1
inhibitor LY2606368 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.